Jieming Gao

Jieming Gao is a highly skilled scientist with a focus on vaccine and drug product development. Currently serving as Scientist II at CSL since 2019, Jieming leads the mRNA vaccine drug product process development, specifically for Covid-19 and Influenza. Prior experience includes a role as a Scientist at Vir Biotechnology, Inc. from 2016 to 2019, where Jieming worked on gene editing (CRISPR) for HPV therapy and hCMV vaccine development for HIV/TB immunotherapy. Jieming's career began as an Assistant Scientist at the University of Wisconsin-Madison from 2014 to 2016, specializing in protein formulation and small molecular synthesis for anticancer and anti-fungal applications. Jieming holds postdoctoral degrees in Pharmaceutical Sciences from the University of Wisconsin-Madison and Pharmaceutics from Rutgers University–New Brunswick, as well as a PhD in Materials Science from Southwest Jiaotong University.